BIO-TECHNE TO HIGHLIGHT NOVEL SOLUTIONS FOR CANCER AND CARRIER SCREENING AT AMP 2024 ANNUAL MEETING & EXPO

PR Newswire11-14

Customers will present data from their use of novel assays and kits; company will host educational workshops and discussions for attendees MINNEAPOLIS, Nov. 14, 2024 /PRNewswire/ -- Bio-Techne ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483879192?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/3bH.cu6ANt8gtC1Pav0aHQ--~B/aD0xNDY7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f5bd457eba951c97e17e98b5c3c3878c","is_english":true,"pubTime":"2024-11-14 20:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2483879192","market":"us","top_or_hot":-1,"title":"BIO-TECHNE TO HIGHLIGHT NOVEL SOLUTIONS FOR CANCER AND CARRIER SCREENING AT AMP 2024 ANNUAL MEETING & EXPO","media":"PR Newswire","content":"<div>\n<p>Customers will present data from their use of novel assays and kits; company will host educational workshops and discussions for attendees\nMINNEAPOLIS, Nov. 14, 2024 /PRNewswire/ -- Bio-Techne ...</p>\n\n<a href=\"https://finance.yahoo.com/news/bio-techne-highlight-novel-solutions-120000096.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BIO-TECHNE TO HIGHLIGHT NOVEL SOLUTIONS FOR CANCER AND CARRIER SCREENING AT AMP 2024 ANNUAL MEETING & EXPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBIO-TECHNE TO HIGHLIGHT NOVEL SOLUTIONS FOR CANCER AND CARRIER SCREENING AT AMP 2024 ANNUAL MEETING & EXPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-14 20:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/bio-techne-highlight-novel-solutions-120000096.html><strong>PR Newswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Customers will present data from their use of novel assays and kits; company will host educational workshops and discussions for attendees\nMINNEAPOLIS, Nov. 14, 2024 /PRNewswire/ -- Bio-Techne ...</p>\n\n<a href=\"https://finance.yahoo.com/news/bio-techne-highlight-novel-solutions-120000096.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FOR","symbol_name":"福里斯特","start_time":0,"source_url":"https://finance.yahoo.com/news/bio-techne-highlight-novel-solutions-120000096.html","article_id":"2483879192","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/3bH.cu6ANt8gtC1Pav0aHQ--~B/aD0xNDY7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f5bd457eba951c97e17e98b5c3c3878c"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/bio-techne-highlight-novel-solutions-120000096.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2483879192","pubTimestamp":1731585600,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Customers will present data from their use of novel assays and kits; company will host educational workshops and discussions for attendees. MINNEAPOLIS, Nov. 14, 2024 /PRNewswire/ -- Bio-Techne Corporation  today announced its lineup of presentations and activities for the Association for Molecular Pathology  2024 Annual Meeting & Expo, taking place November 19-23 in Vancouver, British Columbia. Asuragen, a Bio-Techne brand, will be exhibiting and showcasing its latest research products for breast cancer monitoring and carrier screening in booth #811.At the AMP 2024 Annual Meeting & Expo, Asuragen will host, sponsor, or participate in a number of activities and presentations.ESR1 & Beyond: Leveraging Exosomes for Highly-Sensitive Variant Detection on qPCRThis workshop will showcase the design and performance of the QuantideX qPCR ESR1 exoMutation Kit combined with the ExoLution Plus cfDNA + exoRNA Isolation Kit to achieve analytical sensitivity of ≤0.1% across 11 ESR1 mutations, utiliz","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"FOR":"福里斯特","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","BK4135":"资产管理与托管银行","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK4024":"房地产开发","LU0106831901.USD":"贝莱德世界金融基金A2","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","BIO":"Bio Rad实验室","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","AMP":"阿莫斯莱斯金融","IE00B19Z6F94.USD":"Legg Mason Royce - US Smaller Companies A Acc USD","BK4121":"生命科学工具和服务","TECH":"Techne Corporation","IE0034390439.USD":"FTGF ROYCE US SMALLER COMPANIES \"A\" (USD) D","BK4588":"碎股","BK4123":"调查和咨询服务","EXPO":"毅博科技咨询"},"translate_title":"BIO-TECHNE将在AMP 2024年年会暨博览会上重点介绍癌症和携带者筛查的新颖解决方案","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIO":1,"TECH":1,"FOR":1,"EXPO":1,"AMP":1},"content_text":"Customers will present data from their use of novel assays and kits; company will host educational workshops and discussions for attendees\nMINNEAPOLIS, Nov. 14, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced its lineup of presentations and activities for the Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo, taking place November 19-23 in Vancouver, British Columbia. Asuragen, a Bio-Techne brand, will be exhibiting and showcasing its latest research products for breast cancer monitoring and carrier screening in booth #811.\n\"The Association for Molecular Pathology is a leading voice in the world of clinical molecular testing. We look forward to its meeting every year to discuss the latest advances in molecular diagnostics and how they can be deployed for improved laboratory outcomes,\" said Dr. Matt McManus, President of Bio-Techne's Diagnostics & Spatial Biology Segment. \"This year, we're excited to highlight important new products that will help labs streamline data collection and analysis in critical areas including metastatic breast cancer and carrier screening.\"\nAt the AMP 2024 Annual Meeting & Expo, Asuragen will host, sponsor, or participate in a number of activities and presentations.\nESR1 & Beyond: Leveraging Exosomes for Highly-Sensitive Variant Detection on qPCRThis workshop will showcase the design and performance of the QuantideX® qPCR ESR1 exoMutation Kit combined with the ExoLution Plus cfDNA + exoRNA Isolation Kit to achieve analytical sensitivity of  ≤0.1% across 11 ESR1 mutations, utilizing the power of cfDNA and exosomal RNA to deliver best-in-class performance using commonly-available qPCR instruments.\nSpeaker: Brian Haynes, PhD,  Bio-Techne Diagnostics DivisionDate and time: Wednesday, November 20, 3:00-3:50 PM PSTLocation: Room 212/213\nLong-Range PCR Meets Long-Read Sequencing: An Assay for 11 Hard-to-Decipher, High-Frequency Carrier Screening Associated GenesThis workshop will focus on the design and performance of the AmplideX® Nanopore Carrier Plus Kit, combining AmplideX PCR chemistry with the Oxford Nanopore® platform to identify the most challenging genetic alterations like CNVs, large inversions, and pseudogenes using a consolidated workflow.\nSpeaker: Paul A. Wadsworth, MD, PhD, Resident Physician, Pathology, Stanford UniversityDate and time: Wednesday, November 20, 12:00-12:50 PM PSTLocation: Room 114/115\nFireside Chat: LDT Compliance in an Uncertain EnvironmentWith so much uncertainty around the FDA's laboratory-developed test (LDT) rule, it is challenging for laboratory leaders to make firm plans for how to achieve compliance. This session will consider three different tactical approaches for stage I of the rule: a) labs actively preparing for compliance; b) labs preparing, but cautiously using resources; and c) labs that are taking a 'wait and see' approach.\nDiscussion Leader: Jordan Laser, MD, AsuragenDate and time: Wednesday, November 20, 5:15-6:15 PM PSTLocation: Room 211\nPOSTERS\nVerification of an RT-qPCR Assay System for Liquid Biopsy Surveillance of Treatment-Resistant ESR1 MutationsPresenting author: Blaine Caughron, AsuragenPoster info: G095, Genetics; Saturday, November 23, 9:15 am -10:15 am\nVerification of an Amplification-Based Nanopore Sequencing Assay and Software to Genotype Complex, Clinically-Relevant Variants in 11 Hard-to-Decipher Genes with High Carrier FrequenciesPresenting author: Connor A. Parker, AsuragenPoster info: G094, Genetics; Friday, November 22, 9:15 am -10:15 am\nFreeze-Dried, Worry Thawed: Armored RNA New Lyophilized Controls Offer Potential to Advance Molecular Testing in Resource Limited SettingsPresenting author: Deepa Eveleigh, AsuragenPoster info: ID046, Infectious Disease; Friday, November 22, 9:15 am -10:15 am\nBeta Evaluation of a Panel of 11 Challenging Genes Using ONT/AmplideX ChemistryPresenting author: Anne-Sophie Lebre, Professor of Human Genetics & Clinical Molecular Geneticist, Reims Medical School & University HospitalPoster info: G013, Genetics; Saturday, November 23, 9:15am -10:15am\nStop by the Asuragen booth (#811) to learn more about the company's products for clinical laboratories. We will also be providing free, professional-quality headshots to all AMP attendees who visit our booth on Thursday or Friday.\nFor more information about Asuragen's AMP 2024 activities, please visit https://www.bio-techne.com/about/events/association-molecular-pathology.\nAbout Bio-Techne\nBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has over 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.\nContact:David Clair, Vice President, Investor Relations & Corporate Developmentdavid.clair@bio-techne.com612-656-4416\n\n\n\n\n\n View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-highlight-novel-solutions-for-cancer-and-carrier-screening-at-amp-2024-annual-meeting--expo-302305212.html\nSOURCE Bio-Techne Corporation","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483879192"}